Oral Semaglutide Failed to Slow Clinical Progression in Early Alzheimer's Disease Across Global Phase 3 Trials

Two large, randomized, double-blind, placebo-controlled phase 3 trials, named EVOKE and EVOKE+, evaluated the efficacy of oral semaglutide in participants with amyloid-confirmed early Alzheimer's disease. A total of 3,808 individuals were randomly assigned across 566 sites in 40 countries. Participants ranged from 55 to 85 years of age and had either mild cognitive impairment or mild dementia due to Alzheimer's disease. The primary objective was to assess the change in Clinical Dementia Rating-Sum of Boxes score from baseline to week 104. Oral semaglutide was administered at flexible doses up to 14 mg once daily, while the control group received matching placebo tablets.

The results indicated that oral semaglutide did not demonstrate a statistically significant difference compared with placebo in slowing cognitive decline. In the EVOKE trial, the mean change in CDR-SB score was 2.3 for the semaglutide group and 2.3 for the placebo group, with a p-value of 0.57. Similarly, in the EVOKE+ trial, the mean change was 2.2 for semaglutide and 2.1 for placebo, yielding a p-value of 0.46. These findings suggest that the drug offers no meaningful clinical benefit for delaying disease progression in this specific population.

Safety and tolerability profiles were consistent with those observed in other indications for semaglutide. Treatment-emergent adverse events occurred in 91.2% of participants receiving semaglutide versus 84.8% in the placebo group. Five fatalities were considered treatment-related by investigators, including one in the semaglutide group and four in the placebo group. Discontinuation rates due to adverse events were not explicitly detailed in the provided data, but the overall safety profile did not preclude use based on the current evidence.

The lack of efficacy is a critical finding for clinicians managing patients with early Alzheimer's disease. Despite the drug's success in type 2 diabetes and obesity, its mechanism does not translate to cognitive preservation in this context. This underscores the complexity of Alzheimer's pathology and the need for therapies targeting specific neurodegenerative pathways rather than metabolic effects alone. Clinicians should not expect oral semaglutide to alter the natural history of the disease.

Limitations of the study include the inability to detect subtle benefits that might emerge over longer follow-up periods beyond 156 weeks. Additionally, the absence of reported secondary outcomes limits the understanding of potential benefits in specific domains such as daily functioning or quality of life. The funding source, Novo Nordisk, introduces potential bias concerns, though the study design mitigates this through independent data monitoring and pre-specified analysis plans.

In conclusion, oral semaglutide is not an effective treatment for slowing clinical progression in early Alzheimer's disease. Healthcare providers should inform patients that current evidence does not support its use for this indication. Future research should focus on novel mechanisms that directly address amyloid or tau pathology to achieve meaningful clinical improvements. Until such therapies are available, management strategies must rely on established supportive care and symptomatic treatments.